Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer

Prostate Cancer and Prostatic Diseases volume 14, pages 206–218 (2011)Cite this article

Subjects

Abstract

Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277–300.

    Article  PubMed  Google Scholar 

  2. Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.

    Article  CAS  PubMed  Google Scholar 

  3. Matsunaga N, Kaku T, Ojida A, Tanaka T, Hara T, Yamaoka M et al. C(17,20)-lyase inhibitors: design, synthesis and structure–activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17,20)-lyase inhibitors. Bioorg Med Chem 2004; 12: 4313–4336.

    Article  CAS  PubMed  Google Scholar 

  4. Vasaitis TS, Bruno RD, Njar VC . CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol 2010; e-pub ahead of print.

  5. Dreicer R, Agus DB, MacVicar GR, Wang J, MacLean D, Stadler WM . Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I/II, open-label study. J Clin Oncol 2010; 28 (Suppl): abstract 3084.

    Article  Google Scholar 

  6. Chen Y, Clegg NJ, Scher HI . Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009; 10: 981–991.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010; 107: 16759–16765.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787–790.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 2010; 375: 1437–1446.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 2011; 71: 480–488.

    Article  CAS  PubMed  Google Scholar 

  11. Attard G, Cooper CS, de Bono JS . Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009; 16: 458–462.

    Article  CAS  PubMed  Google Scholar 

  12. Sadar MD . Small molecule inhibitors targeting the ‘Achilles heel’ of androgen receptor activity. Cancer Res 2011; 71: 1208–1213.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem 2005; 48: 2972–2984.

    Article  CAS  PubMed  Google Scholar 

  14. Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK et al. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther 2008; 7: 2348–2357.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sawyers CL . New insights into the prostate cancer genome and therapeutic implications. Proceedings of the Prostate Cancer Foundation Annual Scientific Retreat, Washington, DC, 2010.

    Google Scholar 

  16. Drake CG, Jaffee E, Pardoll DM . Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90: 51–81.

    Article  CAS  PubMed  Google Scholar 

  17. Hodi FS . Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2007; 13: 5238–5242.

    Article  CAS  PubMed  Google Scholar 

  18. Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA 1999; 96: 15074–15079.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP . A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007; 13: 1810–1815.

    Article  CAS  PubMed  Google Scholar 

  20. Beer TM, Slovin SF, Higano CS, Tejwani S, Dorff TB, Stankevichet E et al. Phase I trial of ipilimumab alone and in combination with radiotherapy in patients with metastatic castration resistant prostate cancer. J Clin Oncol 2008; 26 (Suppl): abstract 5004.

  21. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009; 69: 609–615.

    Article  CAS  PubMed  Google Scholar 

  22. Gerritsen W, van den Eertwegh AJ, de Gruijl T, van den Berg HP, Scheper RJ, Sackset N et al. Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2008; 26 (Suppl): abstract 5146.

  23. Dillard T, Yedinak CG, Alumkal J, Fleseriu M . Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010; 13: 29–38.

    Article  CAS  PubMed  Google Scholar 

  24. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167–3175.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009; 27: 2022–2029.

    Article  CAS  PubMed  Google Scholar 

  27. Zoubeidi A, Chi K, Gleave M . Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 2010; 16: 1088–1093.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Miyake H, Nelson C, Rennie PS, Gleave ME . Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000; 60: 2547–2554.

    CAS  PubMed  Google Scholar 

  29. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME . Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002; 50: 179–188.

    Article  CAS  PubMed  Google Scholar 

  30. Gleave M, Miyake H . Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol 2005; 23: 38–46.

    Article  CAS  PubMed  Google Scholar 

  31. Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 resensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 2008; 102: 389–397.

    Article  CAS  PubMed  Google Scholar 

  32. Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 4247–4254.

    Article  CAS  PubMed  Google Scholar 

  33. Ryan BM, O'Donovan N, Duffy MJ . Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009; 35: 553–562.

    Article  CAS  PubMed  Google Scholar 

  34. Talbot DC, Ranson M, Davies J, Lahn M, Callies S, André V et al. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res 2010; 16: 6150–6158.

    Article  CAS  PubMed  Google Scholar 

  35. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 3872–3880.

    Article  CAS  PubMed  Google Scholar 

  36. Wheeler DL, Iida M, Dunn EF . The role of Src in solid tumors. Oncologist 2009; 14: 667–678.

    Article  CAS  PubMed  Google Scholar 

  37. Araujo J, Logothetis C . Targeting Src signaling in metastatic bone disease. Int J Cancer 2009; 124: 1–6.

    Article  CAS  PubMed  Google Scholar 

  38. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide, a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658–6661.

    Article  CAS  PubMed  Google Scholar 

  39. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185–9189.

    Article  CAS  PubMed  Google Scholar 

  40. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY et al. Targeting Src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008; 68: 3323–3333.

    Article  CAS  PubMed  Google Scholar 

  41. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15: 7421–7428.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Araujo J, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1/2 study. Cancer 2011 (in press).

  43. Lara Jr PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 2009; 20: 179–184.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Adjei AA, Cohen RB, Kurzrock R, Gordon GS, Hangauer D, Dyster L et al. Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed Src inhibitor, in patients with advanced malignancies. J Clin Oncol 2009; 27 (Suppl): abstract 3511.

  45. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932–1936.

    CAS  PubMed  Google Scholar 

  46. Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S et al. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 2002; 8: 2714–2724.

    CAS  PubMed  Google Scholar 

  47. Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer: survival results of CALGB 90401. J Clin Oncol 2010; 28 (Suppl): abstract LBA4511.

    Article  Google Scholar 

  48. Halabi S, Kelly WK, George DJ, Morris MJ, Kaplan EB, Small EJ . Comorbidities predict overall survival in men with metastatic castrate-resistant prostate cancer. J Clin Oncol 2011; 29 (Suppl): abstract 189.

  49. Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14: 209–214.

    Article  CAS  PubMed  Google Scholar 

  50. Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009; 103: 1636–1640.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009; 20: 913–920.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT, Galsky MD et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010; 21: 319–324.

    Article  CAS  PubMed  Google Scholar 

  53. Zurita AJ, Liu G, Hutson T, Kozloff M, Shore N, Wilding G et al. Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2009; 27 (Suppl): abstract 5166.

  54. Pfizer Inc. Pfizer discontinues phase 3 trial of sunitinib in advanced castration-resistant prostate cancer (press release 9/27/2010).http://www.pfizer.com/news/press_releases/pfizer_press_release_archive.jsp#guid=discontinue_phase_3_trial_sutent_092710&source=RSS_2010&page=4 (accessed date 3 October 2011).

  55. Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer. Invest New Drugs 2007; 25: 445–451.

    Article  CAS  PubMed  Google Scholar 

  56. Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002; 60: 1113–1117.

    Article  PubMed  Google Scholar 

  57. Christensen JG, Burrows J, Salgia R . c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005; 225: 1–26.

    Article  CAS  PubMed  Google Scholar 

  58. Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z . The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 2007; 67: 967–975.

    Article  CAS  PubMed  Google Scholar 

  59. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 2010; 70: 10090–10100.

    Article  CAS  PubMed  Google Scholar 

  60. Smith DC, Spira A, De Greve J, Hart H, Holbrechts S, Lin CC et al. Phase 2 study of XL184 in a cohort of patients with castration resistant prostate cancer and measurable soft tissue disease. Proceedings of the Annual EORTC Conference, Berlin, Germany, 2010, abstract 406.

    Google Scholar 

  61. Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N et al. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate 2006; 66: 1768–1778.

    Article  CAS  PubMed  Google Scholar 

  62. Björk P, Björk A, Vogl T, Stenström M, Liberg D, Olsson A et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via their binding to quinoline carboxamides. PLoS Biol 2009; 7: e97.

    Article  CAS  PubMed  Google Scholar 

  63. Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Bjork A et al. A randomized, multicenter, international phase II study of tasquinimod in chemotherapy-naïve patients with metastatic castrate-resistant prostate cancer. J Clin Oncol 2010; 28 (Suppl): abstract 4510.

  64. Sarker D, Reid AH, Yap TA, de Bono JS . Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15: 4799–4805.

    Article  CAS  PubMed  Google Scholar 

  65. Vivanco I, Sawyers CL . The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489–501.

    Article  CAS  PubMed  Google Scholar 

  66. Amato RJ, Jac J, Mohammad T, Saxena S . Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer 2008; 6: 97–102.

    Article  CAS  PubMed  Google Scholar 

  67. Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA et al. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res 2010; 16: 3057–3066.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Wu L, Birle DC, Tannock IF . Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005; 65: 2825–2831.

    Article  CAS  PubMed  Google Scholar 

  69. Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL, Corey E . RAD001 (everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 2008; 68: 861–871.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Thomas G, Speicher L, Reiter R, Ranganathan S, Hudes G, Strahs A et al. Demonstration that temsirolimus preferentially inhibits the mTOR pathway in the tumors of prostate cancer patients with PTEN deficiencies. Proceedings of AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA, 2005, abstract C131.

    Google Scholar 

  71. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65: 7052–7058.

    Article  CAS  PubMed  Google Scholar 

  72. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500–1508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Ross RW, Manola J, Oh WK, Ryan C, Kim J, Rastarhuyeva I et al. Phase I trial of RAD001 and docetaxel in castration-resistant prostate cancer with FDG-PET assessment of RAD001 activity. J Clin Oncol 2008; 26 (Suppl): abstract 5069.

  74. Zhang W, Zhu J, Efferson CL, Ware C, Tammam J, Angagaw M et al. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a PTEN-deficient mouse model of prostate cancer. Cancer Res 2009; 69: 7466–7472.

    Article  CAS  PubMed  Google Scholar 

  75. Armstrong AJ, Kemeny G, Turnbull JD, Chao C, Winters C, Fesko YA et al. Impact of temsirolimus and anti-androgen therapy on circulating tumor cell5(CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): a phase II study. J Clin Oncol 2010; 28 (Suppl): abstract TPS249.

    Article  Google Scholar 

  76. Emmenegger U, Sridhar SS, Booth CM, Kerbel R, Berry SR, Ko Y . A phase II study of maintenance therapy with temsirolimus after response to first-line docetaxel chemotherapy in castration-resistant prostate cancer. J Clin Oncol 2010; 28 (Suppl): abstract TPS246.

  77. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S . Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 2007; 121: 1424–1432.

    Article  CAS  PubMed  Google Scholar 

  78. Sun X, Huang J, Homma T, Kita D, Klocker H, Schafer G et al. Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res 2009; 29: 1739–1743.

    CAS  PubMed  Google Scholar 

  79. Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, Troyer DA et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 2007; 13: 3860–3867.

    Article  CAS  PubMed  Google Scholar 

  80. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH et al. Akt activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-Myc expression. J Biol 2004; 279: 2737–2746.

    CAS  Google Scholar 

  81. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, García-Echeverría C et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 2009; 106: 268–273.

    Article  CAS  PubMed  Google Scholar 

  82. Courtney KD, Corcoran RB, Engelman JA . The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28: 1075–1083.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Baselga J, De Jonge MJ, Rodon J, Burris HA, Birle DC, De Buck SS et al. A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2010; 28 (Suppl): abstract 3003.

  84. Burris H, Rodon J, Sharma S, Herbst RS, Tabernero J, Infante JR et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients with advanced solid tumors. J Clin Oncol 2010; 28 (Suppl): abstract 3005.

  85. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M et al. Insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 as predictors of advanced stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099–1106.

    Article  CAS  PubMed  Google Scholar 

  86. Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L et al. Increased insulin-like growth factor-1 receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004; 64: 8620–8629.

    Article  CAS  PubMed  Google Scholar 

  87. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL et al. In vivo effects of the human type-1 insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005; 11: 3065–3074.

    Article  CAS  PubMed  Google Scholar 

  88. Plymate SR, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P et al. An antibody targeting the type-1 insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res 2007; 13: 6429–6439.

    Article  CAS  PubMed  Google Scholar 

  89. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL . IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007; 13: 5549–5555.

    Article  CAS  Google Scholar 

  90. Higano C, Alumkal J, Ryan CJ, Yu EY, Beer TM, Chandrawansa K et al. A phase II study evaluating the efficacy and safety of single-agent IMC-A12, a monoclonal antibody against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastastic, asymptomatic castration-resistant prostate cancer. J Clin Oncol 2009; 27 (Suppl): abstract 5142.

  91. Gualberto A . Figitumumab (CP-751,871) for cancer therapy. Expert Opin Biol Ther 2010; 10: 575–585.

    Article  CAS  PubMed  Google Scholar 

  92. Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer 2010; 103: 332–339.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Nakayama T, Watanabe M, Suzuki H, Toyota M, Sekita N, Hirokawa Y et al. Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest 2000; 80: 1789–1796.

    Article  CAS  PubMed  Google Scholar 

  94. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 2009; 69: 958–966.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (NCI Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009; 115: 5541–5549.

    Article  CAS  PubMed  Google Scholar 

  96. Rathkopf DE, Chi KN, Vaishampayan U, Hotte US, Vogelzang N, Alumkal J et al. Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer. J Clin Oncol 2009; 27 (Suppl): abstract 5064.

  97. Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, Woo MM et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2010; 66: 181–189.

    Article  CAS  PubMed  Google Scholar 

  98. Hoque MO . DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Rev Mol Diagn 2009; 9: 243–257.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Stresemann C, Lyko F . Modes of action of the DNA methyltransferase inhibitors azacitidine and decitabine. Int J Cancer 2008; 123: 8–13.

    Article  CAS  PubMed  Google Scholar 

  100. Festuccia C, Gravina GL, D'Alessandro AM, Muzi P, Millimaggi D, Dolo V et al. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocr Relat Cancer 2009; 16: 401–413.

    Article  CAS  PubMed  Google Scholar 

  101. Sonpavde G, Aparicio AM, Zhan F, North B, Delaune R, Garbo LE et al. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemo-naïve castration-resistant prostate cancer. Urol Oncol 2010; e-pub ahead of print.

  102. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG . PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10: 293–301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Boss DS, Beijnen JH, Schellens JH . Inducing synthetic lethality using PARP inhibitors. Curr Clin Pharmacol 2010; 5: 192–195.

    Article  CAS  PubMed  Google Scholar 

  104. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1: 315–322.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123–134.

    Article  CAS  PubMed  Google Scholar 

  106. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ et al. ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 2728–2737.

    Article  CAS  PubMed  Google Scholar 

  107. Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 2009; 15: 7277–7290.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

    E S Antonarakis

  2. Department of Medicine, Duke Cancer Institute and the Duke Prostate Center, Duke University, Durham, NC, USA

    A J Armstrong

  3. Department of Surgery, Duke Cancer Institute and the Duke Prostate Center, Duke University, Durham, NC, USA

    A J Armstrong

Authors
  1. E S Antonarakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A J Armstrong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E S Antonarakis.

Ethics declarations

Competing interests

Dr Antonarakis declares no conflicts of interest. Dr Armstrong has served as a consultant for Novartis and Amgen; he is on the speakers bureau for Pfizer/Wyeth, Dendreon, and sanofi-aventis; and he has received research funding from Bristol-Myers Squibb, Imclone, Pfizer/Wyeth, Active Biotech, Medivation, Dendreon, Novartis and sanofi-aventis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Antonarakis, E., Armstrong, A. Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 14, 206–218 (2011). https://doi.org/10.1038/pcan.2011.24

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2011.24

Keywords

Search

Advanced search

Quick links